Skye Bioscience, Inc.
SKYE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $18 | $24 | $46 | $68 |
| Short-Term Investments | $17 | $25 | $13 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $2 | $4 | $2 |
| Total Curr. Assets | $40 | $51 | $63 | $71 |
| Property Plant & Equip (Net) | $1 | $2 | $2 | $2 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $1 | $2 | $2 | $2 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $41 | $52 | $65 | $73 |
| Liabilities | – | – | – | – |
| Payables | $3 | $3 | $2 | $1 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $5 | $5 | $3 | $4 |
| Total Curr. Liab. | $8 | $8 | $5 | $4 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $8 | $8 | $6 | $5 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$172 | -$160 | -$142 | -$131 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $205 | $203 | $201 | $199 |
| Total Equity | $33 | $44 | $59 | $68 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $41 | $52 | $65 | $73 |
| Net Debt | -$18 | -$23 | -$46 | -$68 |